Chronic Smell and Flavor Loss Market

• According to DelveInsight’s analysis, the Chronic Smell and Flavor Loss market in the 7MM was valued at approximately USD 3,615.6 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a compound annual growth rate (CAGR) of 6.5%. This expansion in the 7MM is driven by the introduction of innovative therapies such as CYR-064, and others. 
• Given the high unmet needs, key players in the Chronic Smell and Flavor Loss market include Cyrano Therapeutics, among others, who are actively advancing therapeutic and preventive solutions to address the growing prevalence and management of Chronic Smell and Flavor Loss.
• According to DelveInsight’s estimates, in 2023, there were approximately 257 million total prevalent cases of Chronic Smell and Flavor Loss in the 7MM. Of these, the United States accounted for approximately 34% of the cases, while Germany and Spain represented approximately 15% and 7% of the cases, respectively. These cases are expected to rise driven by factors such as the aging population, chronic diseases, medications and treatments, and improved lifestyle factors. 
• The absence of FDA-approved therapies for Chronic Smell and Flavor Loss highlights a critical unmet need, driving ongoing research and development in emerging pipelines to address this sensory dysfunction, particularly post-viral sequelae such as COVID-19-induced anosmia.

DelveInsight’s “Chronic Smell and Flavor Loss Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of chronic smell and flavor loss, historical and forecasted epidemiology, as well as the chronic smell and flavor loss market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The chronic smell and flavor loss market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM chronic smell and flavor loss market size from 2020 to 2034. The report also covers chronic smell and flavor loss treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Chronic Smell and Flavor Loss Treatment Market

Chronic Smell and Flavor Loss Overview

Olfactory dysfunction (OD) and gustatory dysfunctions encompass a spectrum of sensory impairments characterized by reduced or distorted abilities to smell and taste, respectively. With the emergence of the COVID-19 pandemic, these disorders have gained prominence, particularly as anosmia and hyposmia became prevalent symptoms among infected individuals, especially in Europe. Gustatory disturbances, including hypogeusia, dysgeusia, phantogeusia, and ageusia, are often associated with various etiologies such as viral infections, neurological damage, autoimmune conditions, and environmental exposures. The American Academy of Otolaryngology and the British Association of Otorhinolaryngology advocate for recognizing chemosensitive disorders as primary indicators of COVID-19. Given the overlapping neural pathways between taste and olfactory systems, inflammatory damage in these areas may lead to concurrent sensory dysfunctions, manifesting as a wide range of symptoms from complete loss to altered perception of taste and smell, underscoring the need for targeted research and therapeutic interventions in this evolving field.

Chronic Smell and Flavor Loss Diagnosis

Diagnosis of smell and taste disorders typically involves a comprehensive evaluation by an otolaryngologist (ENT specialist) to identify the underlying etiology. The process begins with a thorough physical examination, complemented by self-assessment questionnaires and psychophysical assessments to gauge the extent of sensory impairment. Advanced imaging techniques may be employed to visualize anatomical abnormalities or inflammatory changes in the nasal and oral cavities. This multifaceted diagnostic approach ensures accurate identification of potential causes, allowing for targeted interventions to address the specific dysfunctions impacting the patient’s olfactory and gustatory abilities.

Further details related to country-based variations are provided in the report…

Chronic Smell and Flavor Loss Treatment

Treatment options for smell disorders remain limited, primarily effective in cases where nasal pathologies are the underlying cause. Surgical interventions and corticosteroid therapy are the mainstays for addressing these conditions. In contrast, therapeutic strategies for taste disorders, including corticosteroids and vitamin A, lack robust clinical validation, as do acupuncture approaches. However, zinc gluconate has shown promise in treating idiopathic dysgeusia when administered at a dosage of 140 mg/day for three months. For patients experiencing burning mouth syndrome (BMS), tricyclic antidepressants such as amitriptyline and imipramine have demonstrated efficacy in alleviating abnormal sensations, with additional successful outcomes reported using benzodiazepines like clonazepam or diazepam. This highlights the necessity for further clinical research to establish effective treatments for both olfactory and gustatory disorders.

Chronic Smell and Flavor Loss Epidemiology

• As the market is derived using a patient-based model, the Chronic Smell and Flavor Loss epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Smell and Flavor Loss, Total Diagnosed Cases of Chronic Smell and Flavor Loss, Gender-specific Diagnosed Cases (excluding COVID-19 patients) of Chronic Smell and Flavor Loss, Age-specific Diagnosed Cases (excluding COVID-19 patients) of Chronic Smell and Flavor Loss, and Etiology-specific Cases (excluding COVID-19 patients) of Chronic Smell and Flavor Loss in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. 

• According to DelveInsight’s epidemiology model, in the US, the total prevalent cases of Chronic Smell and Flavor Loss were approximately 86 million in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in testing.
• Among the diagnosed prevalent cases of Chronic Smell and Flavor Loss in EU4 and the UK in 2023, the highest cases were observed in Germany which was approximately 11 million cases and the least number of diagnosed cases were in Spain with approximately 5 million.
• In 2023, gender-specific instances (excluding COVID-19 patients) of Chronic Smell and Flavor Loss were seen to be more in females with around 2.2 million cases as compared to males which were around 1.8 million in the UK.
• According to DelveInsight's epidemiology model, age-specific cases of Chronic Smell and Flavor Loss in the US for 2023 were segmented into the age groups of 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older. The highest prevalence was observed in the 70-79 years age group.
• In 2023, Japan reported 1.6 million cases of Chronic Smell and Flavor Loss due to post-influenza hyposmia and hypogeusia, alongside 1.7 million cases attributed to other causes.

Chronic Smell and Flavor Loss Drug Chapters

Emerging Drugs

CYR-064: Cyrano Therapeutics

CYR-064, developed by Cyrano Therapeutics, is an innovative nasal spray designed to restore olfactory and gustatory function in individuals with chronic sensory loss. This formulation utilizes phosphodiesterase (PDE) inhibitors for intranasal delivery, targeting the mechanisms underlying smell and flavor loss. These conditions typically inhibit stem cell activation mediated by adenylyl cyclase III through cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), reducing growth factor secretion from nasal mucus and impairing stem cell activity in the olfactory epithelium. By delivering PDE inhibitors directly to this region, cAMP and cGMP levels can be increased, potentially restoring olfactory function. Clinical experience has shown that various PDE inhibitors can correct smell loss and, in some cases, restore olfactory function to near-normal levels. CYR-064 is currently in Phase II clinical trials specifically targeting hyposmia, with promising implications for improving outcomes in affected patients.

Note: Further emerging therapies and their detailed assessment will be provided in the final report.

Chronic Smell and Flavor Loss Drug Class Insights

The treatment of Chronic Smell and Flavor Loss involves several classes of interventions aimed at addressing the underlying causes and alleviating symptoms. Corticosteroids are commonly used to reduce inflammation in cases related to nasal pathology, enhancing olfactory function. Tricyclic antidepressants, such as amitriptyline and imipramine, are employed to manage abnormal sensations associated with taste disorders, particularly in conditions like burning mouth syndrome (BMS). Zinc supplements, specifically zinc gluconate, have shown therapeutic potential in idiopathic dysgeusia, offering a targeted approach for taste disturbances. Additionally, benzodiazepines like clonazepam and diazepam are utilized to address anxiety and discomfort associated with sensory dysfunctions. Emerging therapies and further research into neuroprotective agents may also contribute to a more comprehensive treatment landscape for these disorders.

Continued in report…

Chronic Smell and Flavor Loss Market Outlook

Current treatment options for olfactory and gustatory disorders are limited, primarily focusing on corticosteroids and surgical interventions for nasal pathologies, such as polypectomy and pan sinus procedures. For taste disorders, while corticosteroids and vitamin A are often considered, they lack robust clinical evidence. Zinc gluconate has shown some therapeutic effectiveness in idiopathic dysgeusia, and tricyclic antidepressants like amitriptyline and imipramine are utilized for managing burning mouth syndrome (BMS). Cyrano Therapeutics is a major player in this market with its lead product, CYR-064, which comprises phosphodiesterase (PDE) inhibitors formulated for intranasal administration. This candidate is designed to address the common mechanisms underlying smell and flavor loss by inhibiting stem cell activation. Following successful fundraising and patent approvals, Cyrano is advancing toward a Phase II clinical trial in the US. Despite the absence of other pharmaceutical companies actively developing novel treatments, ongoing trials led by universities and research organizations are exploring potential alternatives, driven by increased awareness and the pressing need for effective therapies in the context of rising cases linked to the COVID-19 pandemic.

Continued in report…

Chronic Smell and Flavor Loss Drugs Uptake

This section focuses on the uptake rate of potential Chronic Smell and Flavor Loss drugs expected to be launched in the market during 2020–2034. For example, CYR-064 is expected to enter the US market in 2025 and is projected to have a medium uptake during the forecast period.

Further detailed analysis of emerging therapies drug uptake in the report…

Chronic Smell and Flavor Loss Pipeline Development Activities

The Chronic Smell and Flavor Loss market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline development activities

The Chronic Smell and Flavor Loss market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for Chronic Smell and Flavor Loss.

Chronic Smell and Flavor Loss KOL Views

To keep up with current Chronic Smell and Flavor Loss market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Chronic Smell and Flavor Loss evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the King’s College in London, the University of Washington in Seattle, and European Hospital Georges-Pompidou among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Chronic Smell and Flavor Loss market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician’s View

“As per the KOLs from the UK, there are now millions of people around the world that still have persistent olfactory loss” after COVID-19. It is still very much a neglected area, both in terms of research funding and support from healthcare systems, and it is dismissed in terms of the impact it has on people.”

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging Chronic Smell and Flavor Loss therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based on their ability to improve atrial and ventricular dimension/function and ability to regulate heart rate. 

Further, the therapies’ safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Chronic Smell and Flavor Loss Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. 

The Chronic Smell and Flavor Loss market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Further details will be provided in the report.

The Chronic Smell and Flavor Loss market report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Chronic Smell and Flavor Loss Market Report

• The Chronic Smell and Flavor Loss market report covers a segment of key events, an executive summary, and a descriptive overview of Chronic Smell and Flavor Loss explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Chronic Smell and Flavor Loss market, historical and forecasted market size, and market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Chronic Smell and Flavor Loss market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Chronic Smell and Flavor Loss market.

Chronic Smell and Flavor Loss Market report insights

• Chronic Smell and Flavor Loss Patient Population
• Therapeutic Approaches
• Chronic Smell and Flavor Loss Pipeline Analysis
• Chronic Smell and Flavor Loss Market Size
• Chronic Smell and Flavor Loss Market Trends
• Existing and Future Chronic Smell and Flavor Loss Market Opportunity 

Chronic Smell and Flavor Loss Market report key strengths

• 11 years Forecast
• The 7MM Coverage 
• Chronic Smell and Flavor Loss Epidemiology Segmentation
• Key Cross Competition 
• Attribute analysis
• Chronic Smell and Flavor Loss Drugs Uptake
• Key Chronic Smell and Flavor Loss Market Forecast Assumptions

Chronic Smell and Flavor Loss Market report assessment

• Current Chronic Smell and Flavor Loss Treatment Practices
• Chronic Smell and Flavor Loss Unmet Needs
• Chronic Smell and Flavor Loss Pipeline Product Profiles
• Chronic Smell and Flavor Loss Market Attractiveness
• Qualitative Analysis (SWOT and Attribute Analysis)

Key Questions

Chronic Smell and Flavor Loss Market Insights

• What was the total Chronic Smell and Flavor Loss market size, the market size of Chronic Smell and Flavor Loss by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• How will CYR-064 affect the treatment paradigm of Chronic Smell and Flavor Loss?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the Chronic Smell and Flavor Loss market dynamics and subsequent analysis of the associated trends?

Chronic Smell and Flavor Loss Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Chronic Smell and Flavor Loss? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Smell and Flavor Loss?
• What is the historical and forecasted Chronic Smell and Flavor Loss patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent Chronic Smell and Flavor Loss population during the forecast period (2024–2034)?
• What factors are contributing to the growth of Chronic Smell and Flavor Loss cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Chronic Smell and Flavor Loss? What are the current clinical and treatment guidelines for treating Chronic Smell and Flavor Loss?
• How many companies are developing therapies for the treatment of Chronic Smell and Flavor Loss?
• How many emerging therapies are in the mid-stage and late stage of development for treating Chronic Smell and Flavor Loss?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US? 
• What is the 7MM historical and forecasted Chronic Smell and Flavor Loss market?

Reasons to Buy

• The Chronic Smell and Flavor Loss market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Smell and Flavor Loss market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Chronic Smell and Flavor Loss market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying upcoming Chronic Smell and Flavor Loss companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for Chronic Smell and Flavor Loss, barriers to accessibility of approved therapy, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming Chronic Smell and Flavor Loss companies can strengthen their development and launch strategy.